SUBSCRIBE
SUBSCRIBE

City Therapeutics

NEWS
NextGen
BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets
From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged during a tough fundraising environment in 2025. Check out the 15 battle-tested companies that caught our eye.
January 7, 2026
 · 
2 min read
 · 
Annalee Armstrong
IN THE PRESS
Press Releases
City Therapeutics Announces Submission of Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic for the Treatment of Thromboembolic Diseases
November 11, 2025
 · 
2 min read
Press Releases
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
May 28, 2025
 · 
11 min read
Press Releases
City Therapeutics Expands Executive Team and Board of Directors
April 17, 2025
 · 
4 min read
Press Releases
City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy
January 10, 2025
 · 
3 min read
Press Releases
City Therapeutics Appoints Andy Orth as Chief Executive Officer
January 7, 2025
 · 
3 min read
Press Releases
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine
October 8, 2024
 · 
6 min read
AWARDS
  • NextGen Class of 2026 Badge
JOBS